预约演示
Sotio stops IL-15 trials as cytokine falls short in solid tumors, dealing fresh blow to once-hot mechanism
2023-10-13
临床1期抗体药物偶联物细胞疗法临床申请
Multiple companies are working on IL-15 candidates.
Sotio Biotech has dealt another blIL-15 attempts to establish cytokines as a cornerstone of cancer care, scrapping ongoing studies of its IL-15 superagonist after seeing insufficient efficacy in the clinic.
Sotio Biotechtech raised 280 million euros ($295 million) to advance the IL-15 candidate, nacancerfusp alfa, late in 2021. Months later, BIL-15l Myers Squibb and Nektar Therapeutics’ closely watched IL-2 program imploded, prompting soul searching in the cytokine space, but Sotio forged ahead with its work on the structurally similar IL-15.
Now, Sotio faces its own dark day. A look at interim data on nanrilkefuspIL-15, also knownnanrilkefusp alfaevealed “insufficient efficacyBristol Myers SquibbdevelNektar Therapeuticsndomized trials” iIL-2e settings targeted to date, prompting Sotio to immediately stop enrollSotioin three studies.IL-15
The clinical trials were evaluating nanrilkefusp alfa in combnanrilkefusp alfaLilly’s Erbitux SOT101rck & Co.’s Keytruda in solid tumor patients. While Sotio has abandoned hopes of bringing those combinations to market, it continues to see potential to pair its IL-15 drug candidate with other modalities such as cell therapies. The biotech has seen “promising” preclinical data on a cell therapy combination.
Multiple other companies are workingnanrilkefusp alfates. ImmunityBio got ElifLilly fiErbituxr appMerck & Co.s aKeytrudacytosolid tumor protein, only for the FDA to reject the request on manufacturing grounds. Nektar Therapeutics is running a phase 2/3 clinical IL-15 of an IL-15 receptor agonist, NKTR-255. Novartis is closing in on the end of a phase 1 trial of its IL-15 prospect, NIZ985, but stopped enrollment well short of its goal.
Sotio retains an interest in cytokines, IL-15g that its neImmunityBioon PD-1-inhibiting candidate is set to enter the clinic in the second quarter of next yeaFDABut its R&D pipeline now skews toward antibody-drNektar Therapeuticsdality with a star that has risen as enthusiaIL-15 receptor agonistalNKTR-255.NovartisIL-15NIZ985
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。